1M. Shiraishi,T. Kamo,M. Hotta,S. Nemoto,J. Oshima,H. Sugihara,S. Yasaki,M. Kawakami,Y. Takahashi,S. Shimojo. Usefulness of switching to cabergoline from other dopamine agonists in patients with advanced Parkinson’s disease[J] 2004,Journal of Neural Transmission(6):725～732
2G. Linazasoro. Conversion from dopamine agonists to pramipexole[J] 2004,Journal of Neurology(3):335～339
3A. Clarke,F. Brewer,E. S. Johnson,N. Mallard,F. Hartig,S. Taylor,T. H. Corn. A new formulation of selegiline: improved bioavailability and selectivity for MAO-B inhibition[J] 2003,Journal of Neural Transmission(11):1241～1255
4A. Clarke,E. S. Johnson,N. Mallard,T. H. Corn,A. Johnston,M. Boyce,S. Warrington,D. G. MacMahon. A new low-dose formulation of selegiline: clinical efficacy, patient preference and selectivity for MAO-B inhibition[J] 2003,Journal of Neural Transmission(11):1257～1271
